{"id":12455,"date":"2026-04-28T11:35:57","date_gmt":"2026-04-28T11:35:57","guid":{"rendered":"https:\/\/globalnewstoday.uk\/index.php\/2026\/04\/28\/novartis-sales-dip-as-generics-pressure-intensifies-radioequivalents-loom-biospace\/"},"modified":"2026-04-28T11:35:57","modified_gmt":"2026-04-28T11:35:57","slug":"novartis-sales-dip-as-generics-pressure-intensifies-radioequivalents-loom-biospace","status":"publish","type":"post","link":"https:\/\/globalnewstoday.uk\/index.php\/2026\/04\/28\/novartis-sales-dip-as-generics-pressure-intensifies-radioequivalents-loom-biospace\/","title":{"rendered":"Novartis\u2019 sales dip as generics pressure intensifies, radioequivalents loom – BioSpace"},"content":{"rendered":"

iStock, beast01<\/a><\/span>
Looming competition for Novartis\u2019 radioligand portfolio will have \u201cminimal effect\u201d on market performance in the coming years, CEO Vas Narasimhan contended, as the Swiss pharma faces pressures from incoming generic versions of Lutathera.
Narasimhan was responding to a question about the recent tentative approval<\/a><\/span> for a generic competitor to Novartis\u2019 radiopharma therapy Lutathera, indicated for gastroenteropancreatic neuroendocrine tumors (GEP-NET), during a Tuesday morning call with reporters as the pharma\u2019s presented first-quarter earnings results<\/a><\/span>.
The FDA last month cleared Lantheus\u2019 product as the first radioequivalent therapy for Lutathera for the same indication. Narasimhan emphasized confidence in the pharma\u2019s \u201cstrong market position\u201d for Lutathera, with hundreds of activated treatment centers and years of reliable and timely drug deliveries.
The pharma\u2019s certainty in the resilience of its business against competitive threats extends beyond Lutathera and radiopharma, and comes even as generics have pulled down the company\u2019s quarterly performance. In the first quarter, Novartis\u2019 net sales slid 5% year-on-year to $13.11 billion, versus $13.23 billion in the same period last year. The pharma attributed this dip to generic erosion in the U.S.
Net income dropped 13% year-on-year and earnings-per-share, which came out to $1.65, was 11% lower than in Q1 last year.
Much of the market erosion was for the company\u2019s blockbuster heart failure drug Entresto, sales of which plummeted 46% from Q1 2025 to $1.3 billion. Cosentyx, indicated for various immune disorders, saw a 2% dip in sales to $1.57 billion, though this was driven not by competitive erosion but by revenue adjustments, according to the company.
Together, Cosentyx and Entresto were more than enough to offset the sales growth across most of Novartis\u2019 pipeline, but chief financial officer Mukul Mehta told reporters Tuesday that this negative trend won\u2019t last.
\u201cWe do expect growth to return to our [profit-and-loss] second half of this year,\u201d Mehta said, at which point growth from the rest of the commercial portfolio will start to overtake generic erosion.
Despite the topline drag, product sales showed positive trends across the board. One of Novartis\u2019 top-performing drugs was the breast cancer drug Kisqali, which surged 55% year-on-year to bring in $1.52 billion. Also helping drive growth for the pharma is multiple sclerosis injection Kesimpta, which made $1.16 billion in Q1, a 26% increase. The radiopharma therapy Pluvicto, approved for prostate cancer, grew 70% to hit $642 million in sales.
As for the future of Lutathera, Narasimhan emphasized Novartis\u2019 strong patent protection. Lantheus\u2019 radioequivalent received only tentative approval, meaning that while the regulator has deemed the application worthy of approval, Lantheus will have to wait for a 30-month stay to expire before the product can be marketed, according to a news release<\/a><\/span> from the biotech last month. The stay, triggered by patent litigation brought by Novartis in January 2024<\/a><\/span>, will expire in June.
Narasimhan on Tuesday said that the Lantheus approval is an \u201cimportant precedent\u201d for the radiopharma space that has allowed Novartis to \u201cshow how [radioligand therapy] patents should be upheld in the courts.\u201d
\u201cWe believe our patents are fully valid and we\u2019ll continue to defend them,\u201d Narasimhan said.
Get daily news updates when you subscribe to GenePool!
\u00a9 1985 – 2026 BioSpace.com. All rights reserved. <\/p>\n

source<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

iStock, beast01Looming competition for Novartis\u2019 radioligand portfolio will have \u201cminimal effect\u201d on market performance in the coming years, CEO Vas Narasimhan contended, as the Swiss pharma faces pressures from incoming generic versions of Lutathera.Narasimhan was responding to a question about the recent tentative approval for a generic competitor to Novartis\u2019 radiopharma therapy Lutathera, indicated for […]<\/p>\n","protected":false},"author":1,"featured_media":12456,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[],"class_list":{"0":"post-12455","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-business"},"_links":{"self":[{"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/posts\/12455","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/comments?post=12455"}],"version-history":[{"count":0,"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/posts\/12455\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/media\/12456"}],"wp:attachment":[{"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/media?parent=12455"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/categories?post=12455"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/globalnewstoday.uk\/index.php\/wp-json\/wp\/v2\/tags?post=12455"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}